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Abstract
Background: Epidemiological studies show wide variability in the occurrence of cannabis smoking and related 
disorders across countries. This study aims to estimate cross-national variation in cannabis users' experience of clinically 
significant cannabis-related problems in three countries of the Americas, with a focus on cannabis users who may have 
tried alcohol or tobacco, but who have not used cocaine, heroin, LSD, or other internationally regulated drugs.
Methods: Data are from the World Mental Health Surveys Initiative and the National Latino and Asian American Study, 
with probability samples in Mexico (n = 4426), Colombia (n = 5,782) and the United States (USA; n = 8,228). The 
samples included 212 'cannabis only' users in Mexico, 260 in Colombia and 1,724 in the USA. Conditional GLM with GEE 
and 'exact' methods were used to estimate variation in the occurrence of clinically significant problems in cannabis 
only (CO) users across these surveyed populations.
Results: The experience of cannabis-related problems was quite infrequent among CO users in these countries, with 
weighted frequencies ranging from 1% to 5% across survey populations, and with no appreciable cross-national 
variation in general. CO users in Colombia proved to be an exception. As compared to CO users in the USA, the 
Colombia smokers were more likely to have experienced cannabis-associated 'social problems' (odds ratio, OR = 3.0; 
95% CI = 1.4, 6.3; p = 0.004) and 'legal problems' (OR = 9.7; 95% CI = 2.7, 35.2; p = 0.001).
Conclusions: This study's most remarkable finding may be the similarity in occurrence of cannabis-related problems in 
this cross-national comparison within the Americas. Wide cross-national variations in estimated population-level 
cumulative incidence of cannabis use disorders may be traced to large differences in cannabis smoking prevalence, 
rather than qualitative differences in cannabis experiences. More research is needed to identify conditions that might 
make cannabis-related social and legal problems more frequent in Colombia than in the USA.
Background
Population prevalence and global health burdens associated
with drug dependence and related drug use disorders vary
markedly across world regions [1]. For example, in 2003,
the United Nations Office on Drugs and Crime tallied the
occurrence of cannabis problems in different countries of
the world, based upon administrative reporting systems
from each government (UN, 2003; https://www.unodc.org/
pdf/trends2003_www_E.pdf, last accessed 15 Aug 2009).
According to the UN, in the Americas, the prevalence of
cannabis problems for Mexico was 1%, for Peru, 2-3%, for
Venezuela, 8%, and for the United States (USA), 9-10%
[2]. Most likely, these wide variations in the UN estimates
can be traced back to variations in administrative record-
keeping of each government or to differences in study
methods and instruments used [3,4]. Another possibility is
that these cross-country variations are more than artifactual.
In this instance, there are at least two hypotheses that might
explain the observed variations.
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The first of these two hypotheses is quantitative in origin:
observed variations in cross-country prevalence of canna-
bis-related disorders might simply reflect cross-country
variations in the number of people who have used this drug.
The second hypothesis has to do with more qualitative
between-country differences in what cannabis users experi-
ence once drug use starts. From pharmacology, we can
identify some potential sources of qualitative differences in
these experiences, including cannabis properties and canna-
bis consumption patterns, perhaps involving variations in
the delta-9 tetrahydrocannabinol (THC) content of the local
product [5], how it is ingested, or whether cannabis is con-
sumed with tobacco, alcohol or other illegal drugs concur-
rently [6]. From the social sciences, we can point toward
variations in ambient socio-demographic characteristics
and socio-cultural contexts, defined to encompass laws and
policies, social values, and societal dynamics. Of course,
these two hypotheses are not mutually exclusive in that the
sheer prevalence of cannabis smoking may drive the occur-
rence of cannabis dependence and other cannabis problems
and, in addition, qualitative between-country differences
also may shape the population-level health burdens.
The World Health Organization World Mental Health
Surveys Consortium (WHO, WMHS) has created a new
opportunity to investigate research questions about poten-
tial reasons for cross-site and cross-national variation in
cannabis experiences. The WHMS involves a form of
active surveillance, conducted by coordinated research
teams that follow the same or essentially the same field sur-
vey research protocol. This approach holds constant or con-
strains survey research methods to be similar in order to
produce cross-national and cross-site comparative data
from all the participating countries, with representation of
all WHO regions [7].
In this context, this study's aim is to seek evidence about
actual cross-national variation in the experience of clini-
cally significant cannabis problems (hereinafter termed
"clinical features") as identified in the Spanish-American
heritage populations of the USA, Mexico, and Colombia, as
well as the USA general population. The focus is on general
population participants who have smoked cannabis, and
who may also have tried tobacco and alcoholic beverages
(hereinafter, alcohol), after exclusion of cannabis smokers
who had engaged in illegal use of cocaine, heroin, LSD,
and other internationally regulated drugs (IRD).
The focus on 'cannabis only' users is motivated by com-
plexities introduced when other psychoactive drug com-
pounds are used concurrently, especially illegal drugs or
those prescription drugs used extra-medically. As men-
tioned above, in some countries, cannabis is more likely to
be consumed along with other psychoactive drugs obtained
legally or illegally. To the extent that males are more likely
to be engaged in such drug use patterns, an excess occur-
rence of cannabis problems among males might be traced
back to underlying variations in use of other drugs. This
possibility has prompted regression modeling with covari-
ates and the use of matching procedures, sample restriction
or exclusion rules [8]. Here, the sample restriction approach
(i.e., focus on 'cannabis only' users) and individual-level
matching have been applied.
The focus on the USA, Mexico, and Colombia is moti-
vated by the fact that these were the only three WMHS
Consortium countries with large Spanish-American heri-
tage populations. To date, the only other WMH survey in
the Americas has been conducted in Sao Paulo, Brasil, and
the data from the Sao Paulo site are not yet available for this
report's analyses.
Methods
Participants
The data for this research were gathered as part of the
WMHS and NLAAS initiatives with community samples in
Mexico (n = 5,782), in Colombia (n = 4,426), and in the
USA (n = 8,228). In each country, a cross-sectional multi-
stage probability sample survey design was used to desig-
nate dwelling unit respondents, who then were recruited for
the survey assessment. In the USA, two complementary
survey samples were recruited: (a) a sample of 5,692 com-
munity participants in the National Comorbidity Survey
Replication (NCS-R); and (b) a sample of 2,554 Hispanic
heritage community participants in the NLAAS.
The target population for each of these epidemiological
surveys was defined to include non-institutionalized com-
munity dwelling unit residents, aged 18 years and older. In
Colombia and Mexico, where about 75% of the total popu-
lation resides in urban areas, the sampling frame was
restricted to urban Spanish speakers, yielding a nationally
representative sample for urban populations. In the USA,
the NCS-R sampling frame consisted of English speaking
adult household residents, yielding a nationally representa-
tive sample for both rural and urban populations (USA gen-
eral population). There were no restrictions in the sampling
process based in race-ethnic heritage for the NCS-R. On the
other hand, the NLAAS sampling frame was restricted to
adult household residents with either Hispanic or Asian-
American heritage, yielding a nationally representative
sample of those segments of the US population. The 2,554
Hispanic heritage NLAAS participants (hereinafter, USA
Latinos) self-identified themselves as follows: 57% Mexi-
can heritage, 10% Puerto Rican, 5% Cuban. The rest quali-
fied as 'Other' Latino (about 28%). Participation levels
exceeded 75% for each survey. Consent procedures and the
protocols were approved by research ethics committees in
all countries. The NLAAS and NCS-R datasets qualify as
'public use' datasets; it was necessary to secure permission
from the Mexico and Colombia sites in order to bring their
data into this research project on cannabis.Fiestas et al. BMC Public Health 2010, 10:152
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Among 18,454 individuals in these various nationally
representative community samples, and after exclusion of
2,121 cannabis users who had been illegal users of cocaine,
heroin, LSD or other internationally regulated drugs, there
were 2,196 'cannabis only' users (hereinafter, 'CO' users).
We did not exclude cannabis smokers who also had con-
sumed tobacco (about 65%) or alcoholic beverages (about
99%).
Assessment
All surveys used the WMHS version of the WHO Compos-
ite International Diagnostic Interview, version 3.0 (CIDI-
WMH). The Spanish version was prepared with attention to
a standard protocol for translation from English, indepen-
dent back-translation, and a harmonization process,
described elsewhere [7].
The CIDI-WMH involves administration of a fully struc-
tured interview schedule with broad coverage of health and
mental health topics, including psychiatric and behavioral
disturbances. Within this context, the CIDI-WMH includes
modules that present standardized questions on the use of
specific drug compounds, and questions to assess clinical
features associated with drug use disorders, in conformity
with the abuse and dependence definitions and criteria of
the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV; APA, 1994).
The CIDI-WMH module that taps the diagnostic criteria
and features of "DSM-IV Drug Abuse" poses five questions
(see Additional file 1). Four of these questions refer to
work, social and legal problems, as well as to recurrent haz-
ard-laden use. These four questions about the DSM-IV drug
abuse construct were asked to all people who completed the
CIDI-WMH drug disorders module. The fifth question
asked about continued drug use despite experiencing social
problems, and was conditioned on a positive answer to the
social problem question.
It is of note that the CIDI-WMH poses the DSM-IV drug
abuse questions in a way that make them non-specific for
each of the types of drugs just mentioned (i.e., cannabis,
cocaine, heroin, other IRD). This means that when multiple
drugs had been used, we cannot know which specific drug
accounted for the occurrence of a clinical feature. Thus, in
order to focus this investigation on problems specifically
related to cannabis, and to eliminate the influence of other
drugs on the occurrence of these clinical features, an exclu-
sion rule was applied. Here, for this report, the drug users
under study were those whose illegal drug experiences were
limited to cannabis and only cannabis (i.e., they are 'canna-
bis only' users).
It should also be noted that in all four surveys (i.e., NCS-
R, Mexico, Colombia and NLAAS) the "DSM-IV drug
abuse" clinical features module was preceded by a screen-
ing module, which was used to identify respondents who
might have experienced 'clinically significant' problems
with either alcohol or other drugs. This screening module
was administered in Part 1 of all four surveys. It invokes a
broad and non-specific assessment of 'clinically significant'
problems via the following three standardized questions: a)
"Did you ever use alcohol or drugs so much that your fam-
ily or friends worried about you or repeatedly complained
about your use?" b) "Did you ever use alcohol or drugs so
much that it caused repeated arguments or problems either
with your family or friends, people at work or school, or
with the police?" c) "Did you ever use alcohol or drugs so
much that it often interfered with your responsibilities at
work, at school, or at home?." Only those participants who
had tried illegal drugs and experienced at least one of these
'clinically significant' problems were asked DSM-IV drug
abuse module questions.
In total, the DSM-IV drug abuse module was adminis-
tered to 58 (16%) of 353 'cannabis only' (CO) users in the
NLAAS, 69 (27%) of 260 CO users in Colombia, 59 (28%)
of 212 CO users in Mexico, and 262 (19%) of 1,371 CO
users in the NCS-R. Accordingly, the measurement theory
of the research team followed a logic pertinent to the DSM-
IV construct of DSM-IV disorders that first was articulated
by Narrow et al. [9], and that has been discussed by Degen-
hardt and colleagues [10-12]. As discussed, this type of gat-
ing procedure should be highly sensitive, leaving behind
very few cases of drug use disorders of 'clinical signifi-
cance' as required for the DSM criteria. Accordingly, in this
study, we imputed zeros when cannabis-using respondents
failed to meet the 'clinical significance' criterion that is
implicit in the screening module of the CIDI-WMH proto-
col for the assessment of the DSM-IV drug use disorder. It
follows that a standard measurement assumption for these
studies is that no clinically significant drug problems had
occurred unless the drug user had experienced at least one
of the three broad and non-specific problems assessed by
the CIDI-WMH screening module described above. We
will return to this assumption in the discussion section of
this article. Lastly, although the NLAAS assessed cannabis-
associated legal problems, the NLAAS public use dataset
does not include this variable due to concern that its release
might permit inadvertent identification of specific individu-
als, in violation of confidentiality and privacy protections.
Procedure
Details about the coordinated sampling, project plan, and
assessment approaches are available in online reports http://
www.icpsr.umich.edu/cocoon/cpes/using.xml, last accessed
11 Sep 2009), and in a series of journal publications
[1,7,13,14]. A brief overview of the WMHS and NLAAS
research approach follows and appears in Table 1 (Panel 1).
The WMHS and NLAAS assessment had two parts: Part
1 and Part 2. This arrangement was intended to reduce the
questioning burden for the study participants, most of
whom had no illegal drug experience whatsoever. Part 1Fiestas et al. BMC Public Health 2010, 10:152
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was administered to all participants and included core diag-
noses of central interest. These core diagnoses encom-
passed basically mood and anxiety disorders (e.g., major
depression, dysthymia, bipolar disorder, panic attack, gen-
eralized anxiety disorder), with some minor variations
across countries. For example, the alcohol and other drug
use modules, and related disorders modules, were included
in Part 1 for Colombia, Mexico and the NLAAS; for the
NCS-R, these modules were in Part 2.
In general, Part 2 included disorders of secondary interest
to the primary sponsors of the WMHS and NLAAS
(anorexia, bulimia, obsessive compulsive disorder, conduct
disorder, attention deficit disorder, among others). It was
administered to a probability subsample of Part 1 partici-
pants, selected via a computerized algorithm. Basically, in
the NCS-R, the rules for this algorithm included meeting
lifetime history criteria for any of the Part 1 core disorders,
a probabilistic sample of 59% of those participants who
reported behavior problems or psychiatric symptoms but
failed to meet criteria for any of the Part 1 core disorders;
and a probabilistic sample of 25% of all others [14,15].
These variations in probability of selection are taken into
account through appropriate weights during data analysis.
Table 1: Description of the surveys conducted at each site.
Country Survey Sample characteristics* Dates Age Sample size Response 
rate, %**
Part1 Part2
Colombia NSMH Stratified multistage 
clustered area probability 
sample of household 
residents in all urban areas 
of the country 
(approximately 73% of the 
total national population).
2003 18-65 4,426 2,381 88
Mexico M-NCS Stratified multistage 
clustered area probability 
sample of household 
residents in all urban areas 
of the country 
(approximately 75% of the 
total national population).
2001-2002 18-65 5,782 2,362 77
USA NCS-R Stratified multistage 
clustered area probability 
sample of household 
residents, nationally 
representative.
2002-2003 ≥18 9,282 5,692 71
USA NLAAS
(Latino 
sample)
Stratified multistage 
clustered area probability 
sample of household 
residents, nationally 
representative of Latino 
population with special 
supplements of Puerto 
Rican and Cuban people.
2002-2003 ≥18 2,554 348 76
Abbreviations: NSMH, the Colombian National Study of Mental Health; M-NCS, the Mexico National Comorbidity Survey; NCS-R, the US 
National Comorbidity Survey Replication; NLAAS, the National Latino and Asian American Study of Mental Health.
*Most World Mental Health surveys are based on stratified multistage clustered area probability household samples in which samples of areas 
equivalent to municipalities or counties in the United States were selected in the first stage followed by 1 or more subsequent stages of 
geographic sampling (eg, towns within counties, blocks within towns, households within blocks) to arrive at a sample of households, in each 
of which a listing of household members was created and 1 or 2 people were selected from this listing to be interviewed. No substitution was 
allowed when the originally sampled household resident could not be interviewed. These household samples were selected from census area 
data in all countries. United States surveys are based on nationally representative household samples, while Colombia and Mexico are based 
on nationally representative household samples in urbanized areas.
**The response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households 
originally sampled, excluding from the denominator households known not to be eligible either because of being vacant at the time of initial 
contact or because the residents were unable to speak the designated languages of the survey.Fiestas et al. BMC Public Health 2010, 10:152
http://www.biomedcentral.com/1471-2458/10/152
Page 5 of 10
Analysis Plan
A standard three-step approach was implemented: i)
explore the marginals (i.e., Tukey-style exploratory data
analysis); ii) analyze/estimate; and iii) explore again (e.g.,
regression diagnostics; evaluate model assumptions about
subgroup variation). Analyses took into account weighting
for sample selection probabilities, post-stratification adjust-
ment factors, and the multi-stage nested structure of the
sampling plan. Taylor series linearization methods were
used for variance estimation when appropriate.
We estimated population subgroup proportions for each
clinical feature of cannabis use in each country's sample of
CO users. A generalized linear model (GLM) with a logis-
tic link function was used to study cross-national variation
in the occurrence of the clinical features. Because these
clinical features are expected to be inter-correlated (i.e.,
clustered within individuals), the generalized estimating
equations (GEE) were used to bring the error structure for
multiple logistic regression into conformity with regression
assumptions that, if ignored, might produce erroneous sci-
entific conclusions and reduced efficiency and precision of
regression estimates [16]. However, for the assessment of
variation in the log odds of continued cannabis smoking
despite awareness of cannabis-caused social problems, a
binary logistic regression model was used, with a subpopu-
lation structure to highlight the subgroup of cannabis smok-
ers who had experienced social problems.
Finally, because the analyses sometimes were based on a
small number of CO users who had experienced clinically
significant problems, we also applied exact methods for
logistic regression [17]. Moreover, to address the notion
that some of the observed associations might be strongly
confounded by male sex and history of alcohol use disor-
ders, (AUD) [6,18], we matched on sex and AUD, and then
fit an exact conditional logistic regression, with covariate
terms as listed above. In our samples, alcohol problems
were present in 22% of CO users in Colombia, 20% in
Mexico, and about 15% in both USA general population
and USA Latino population. We convey the precision of the
odds ratio estimates with 95% confidence intervals as well
as p-values (alpha at 0.05). Analyses were performed in
Stata 10.0 [19] and LogXact 8.0 [20].
Results
Table 2 conveys the distribution by country of the 2,196
respondents who had smoked cannabis but had not engaged
in illegal use of cocaine, heroin, or other internationally
regulated drugs (IRD); as noted above, virtually all had
consumed alcohol and 2/3rds had smoked tobacco. The
cumulative occurrence of CO use was larger in the USA
population at large (NCS-R), followed by the Latino popu-
lation living in the USA (NLAAS), Colombia, and then
Mexico, with statistically robust differences in that order (p
< 0.05). Given that these differences might vary as a func-
tion of the respective cumulative incidence for cannabis
smoking, regardless of the illegal use of other IRD, we esti-
mated the relative proportion of CO users among all canna-
bis users. Thus, in the USA general population (NCS-R),
about 51% 'cannabis ever' users had used cannabis exclu-
sively (95% confidence interval, CI = 49, 54), which was
similar to the corresponding 50% estimate for the USA
Latino population (NLAAS; 95% CI = 45, 56). In contrast,
among 'cannabis ever' users from Colombia, 63% used can-
nabis exclusively (95% CI = 57, 69), and for Mexico the
corresponding estimate was 57% (95% CI = 51, 64).
In testing the hypothesis that the proportion of CO users
among the 'cannabis ever' users was similar across the four
country populations, we found robust differences only in
the contrast of Colombia versus the USA. Specifically, after
adjusting for age and sex, the odds of being a CO user
among the Colombian 'cannabis ever' users was 1.6 times
the NCS-R-estimated odds of being a CO user in the USA
(i.e., adjusted odds ratio, aOR = 1.6; 95% CI = 1.2, 2.1; p =
0.003). Similarly, after adjusting for age and sex, the odds
of being a CO user among the Colombian 'cannabis ever'
users was 1.7 times the NLAAS-estimated odds of being a
CO user among USA Latino 'cannabis ever' users (i.e., aOR
= 1.7; 95% CI = 1.2, 2.4; p = 0.003). There were no robust
differences in other pairwise comparisons (i.e., Mexico ver-
sus USA general population, Mexico versus USA Latinos,
and USA Latinos versus USA general population).
Table 2 also shows the estimated cumulative occurrence
of CO use specific for sex and age across the populations
studied. There were consistently more CO users among
men than among women in Colombia, Mexico and the USA
Latino population. However, in the USA general population
(NCS-R), there was no male-female variation in estimated
cumulative occurrence of 'cannabis only' use. In addition,
for Colombia and Mexico, there was little age-related varia-
tion in occurrence of CO, whereas for the USA Latinos and
general population the estimated cumulative occurrence of
CO use was less frequent among people age 55 years and
older.
The population-specific estimated proportions presented
in Table 3 convey that the experience of cannabis-related
clinical features was quite infrequent among CO users in all
three countries, with weighted frequencies ranging from
1% to 5%. In general, recurrent hazard-laden cannabis
smoking (e.g., driving while intoxicated) and social prob-
lems attributed to cannabis seem to be the most frequent
clinically significant cannabis-related problems, followed
by cannabis-related work problems. Cannabis-related legal
problems were quite infrequent (Table 3).
In the comparison of Colombia CO users with USA CO
users, living in Colombia was associated with greater
occurrence of cannabis-related social and legal problems,
even with statistical adjustment for sex and age. In specific,
CO users in Colombia were more likely to have experi-Fiestas et al. BMC Public Health 2010, 10:152
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enced 'social problems' (aOR = 3.0; 95% CI = 1.4, 6.3; p =
0.004) and 'legal problems' (aOR = 9.7; 95% CI = 2.7, 35.2;
p = 0.001), as compared to CO users in the USA general
population. There were no such associations for work prob-
lems and recurrent hazard-laden use. In addition, there was
some evidence that the USA Latino CO users tended to be
engaged in recurrent hazard-laden use more often than
those in Mexico. However, this finding failed to be statisti-
cally significant by the conventional standard of p < 0.05
after adjusting by sex and age (aOR = 2.9; 95% CI = 1.0,
8.5; p = 0.051). There was no USA Latino v. Mexico varia-
tion in the other cannabis problems under study.
Large confidence intervals for the 'legal problems' esti-
mates in the Colombia-USA contrast implies instability of
estimates due to the small numbers of CO users who experi-
enced this type of problem. Due to the small numbers, we
turned to exact logistic regression and re-estimated the odds
ratio, adjusting for sex and age. Evidence from this 'exact'
analysis helps confirm that, in Colombia, CO users were
more likely to experience 'legal problems' than CO users in
the USA general population (OR = 4.4; 95% CI = 1.1, 19.6;
exact p = 0.039). To provide additional control over possi-
ble confounding by a past history of alcohol use disorders
(AUD) and sex, we formed risk sets after matching on
AUD and sex such that everyone within each separate risk
set had the same values of the AUD and sex variables.
Using the 'exact' conditional logistic regression model with
these AUD- and sex-matched risk sets, the resulting age-
adjusted odds ratio estimate supports an inference of excess
occurrence of cannabis-related legal problems in Colombia
versus in the USA general population (OR = 4.9; 95% CI =
1.1, 23.3; exact p = 0.034).
Finally, for assessment of variations across the study pop-
ulations in the occurrence of continued use of cannabis
despite the user's awareness of social problems due to can-
nabis, the binary logistic regression model was used, with a
restriction to CO users who had experienced cannabis-
related social problems. This analysis disclosed no statisti-
cally robust variation across populations in relation to that
clinical feature (p-values > 0.05 for all pairwise compari-
sons).
Discussion
This study's main findings can be summarized as follows.
Among adults in the USA, about half of the cannabis smok-
ers have used other illegal or internationally regulated
drugs, whereas this was somewhat less common in Colom-
bia and Mexico, where 'cannabis only' use was more com-
mon. We also found that the cannabis problems were
experienced rather infrequently by the CO users, which fol-
Table 2: Estimated cumulative occurrence (%) of cannabis smoking with no other illegal drug use. 
Colombia Mexico Latinos USA (NLAAS) USA (NCS-R)
N* n¥ %**
(95%CI)
N* n¥ %**
(95%CI)
N* n¥ %**
(95%CI)
N* n¥ %**
(95%CI)
All persons 4,426 260 7
(6, 8)
5,782 212 4
(4,5)
2,554 353 15
(13, 17)
5,692 1,371 22
(20, 23)
Sex
Male 1,700 195 11
(9, 13)
2,285 184 9
(7, 10)
1,127 200 20
(17, 22)
2,382 580 23
(20, 25)
Female 2,726 65 3
(2, 4)
3,497 28 1
(<1, 1)
1,427 153 10
(8, 13)
3,310 791 21
(19, 23)
Age Group
18-29 1,431 99 7
(6, 9)
2,060 76 5
(3, 6)
731 161 22
(17, 27)
1,371 408 28
(25, 31)
30-44 1,735 94 6
(4, 7)
2,236 92 5
(4, 7)
931 125 12
(10, 15)
1,826 508 27
(24, 29)
45-54 730 49 8
(5, 11)
840 26 3
(1, 5)
394 46 16
(12, 19)
1,123 319 26
(22, 30)
>55 530 18 6
(2, 10)
646 18 3
(1, 5)
498 21 6
(3, 9)
1,372 136 9
(7, 11)
* Unweighted number of participants (i.e., simple count).
¥ Unweighted number of cannabis-only users (i.e., simple count).
** Indicates weighted data with Taylor series linearization for variance estimation.
Data from WMH and CPES Surveys in Colombia, Mexico, and USA, 2002-3.Fiestas et al. BMC Public Health 2010, 10:152
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lowed a similar pattern for all three countries. However,
there was an exception to that general rule: CO users in
Colombia were more likely to experience cannabis-related
social and legal problems as compared to CO users in the
USA general population. Regrettably, one limitation of this
study involves data on cannabis-related 'legal problems,'
which were assessed in the NLAAS, but the NLAAS prin-
cipal investigators did not release these values due to con-
cern about inadvertent violation of confidentiality and
incomplete privacy protection (e.g., if the survey data were
matched to publicly available data on cannabis offenses).
For this reason, we were unable to compare Colombia's
estimates with those of the US Hispanic subgroups sur-
veyed for the NLAAS, which would have been especially
interesting, given observed greater occurrence of cannabis-
associated legal problems in Colombia.
Another finding of potential interest involves recurrent
hazard-laden cannabis smoking, and the observation that
USA Latino CO users tended to engaged in recurrent haz-
ard-laden use more often than those in Mexico. To the best
of our knowledge, there is neither strong theory nor prior
evidence on recurrent hazard-laden use from prior cross-
national studies of this type, which might have been used to
establish a set of Bayesian priors for this contrast, or to cal-
ibrate statistical power for a more complete balance of Type
I and Type II error. In this context, readers may wish to note
that p = 0.051 is not too distant from the conventional stan-
dard of 0.05. A slightly larger sample might well have pro-
duced p < 0.05 with an effect estimate of this size; this is a
contrast that may deserve future investigation and confir-
mation in future epidemiological studies.
Before detailed discussion, several other limitations
deserve to be mentioned. Despite the size of the overall
samples in each place, there were relatively small numbers
of CO users who had experienced cannabis problems,
according to the CIDI-WMH assessment. In consequence,
no more than a handful of covariate terms could be intro-
duced in the statistical models; statistical power and preci-
sion also were limited. Moreover, there were too few CO
users in the samples to permit a focused study on the recent-
onset cannabis smokers as has been done elsewhere [8].
This constraint also thwarted any detailed probing of male-
female differences, or research on issues of migration and
acculturation, as one might wish to examine in relation to
the experience of specific subgroups of Spanish-speakers in
these samples (e.g., Mexico, Colombia, or other country of
origin for the USA Latinos). In addition, the self-report
character of the assessment of cannabis-related problems
can be expected to introduce some measurement error,
which we suspect might be manifest as 'under-reporting' of
the clinical features if not cannabis smoking per se, as dis-
cussed elsewhere [4,11].
One other possible limitation has to do with design issues
as described in our methods section, especially the CIDI-
WMH focus on 'clinically significant' cannabis problems.
Readers interested in more details about this issue are
Table 3: Estimated cumulative occurrence of each clinical feature related to abuse among 'cannabis only' users, by country 
population. 
Clinical Features Colombia Mexico Latinos USA (NLAAS) USA
(NCS-R)
n¥ %
(95%CI)*
n¥ %
(95%CI)*
n¥ %
(95%CI)*
n¥ %
(95%CI)*
Recurrent hazard-laden smoking 9 3 (1, 5) 7 3 (<1, 5) 15 6 (3, 9) 59 3 (2, 4)
Social problems 13 5 (2, 7) 8 3 (<1, 5) 5 2 (<1, 3) 27 1 (1, 2)
Continued smoking despite 
experiencing these problems‡
9 4 (1, 6) 6 2 (<1, 4) 4 2 (<1, 3) 22 1 (1, 2)
Work problems 8 2 (<1, 4) 6 2 (<1, 4) 5 1 (<1, 3) 24 1 (<1, 2)
Legal problems 6 2 (<1, 4) 3 1 (<1, 2) Not available** 5 Not estimated
¥ These are simple counts of cannabis-only smokers who experienced each clinical feature as listed by row, and by country, before weighting 
the data. The small counts constrained what can be done in relation to original plans for more complex modeling, and placed limits on 
statistical power and precision.
* The estimated percents and 95% CI are based on application of the survey weights and estimation as described in the methods section.
** Data on 'Legal problems' are not publicly available for the NLAAS participants (not released to reduce likelihood of a confidentiality 
violation).
‡This question was asked only to those who gave a positive answer to the query regarding the experience of social problems.
Data from WMH and CPES Surveys in Colombia, Mexico, and USA, 2002-3.Fiestas et al. BMC Public Health 2010, 10:152
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referred to original work by Narrow and colleagues [9] and
to more recent contributions by Degenhardt and colleagues
[10-12], in which it has been found that this particular
CIDI-WMH approach seems to have had no appreciable
influence when the task is to estimate the occurrence of
DSM-IV cannabis dependence and related problems.
A last limitation is the narrow range of cannabis experi-
ences covered in the standardized diagnostic assessments.
In future global health research on cannabis-associated
experiences, it should be possible to extend the coverage of
cannabis experiences in two directions: (a) toward positive
and possible health-enhancing experiences associated with
cannabis consumption (e.g., of the type discussed by Grif-
fiths et al.(2006) [21], as well as appetite-promoting or nau-
sea-reducing effects discussed in the context of medicinal
use of cannabis products); and (b) a more complete cover-
age of craving and the obsession-like or compulsion-like
experiences associated with cannabis dependence syn-
dromes. The global prevalence of cannabis smoking pro-
vides ample justification for this type of focused inquiry.
Despite caveats such as these, this study has the strength
of generally comparable data gathering with a standard
design and implementation protocol across countries as part
of the WMHS initiative. Each population sample in the
three countries was obtained through similar multi-stage
sampling methods with good to excellent participation lev-
els. Each participant completed standardized survey assess-
ments of high quality.
Against this background of limitations and strengths, this
study shows that CO users represent in general a substantial
majority of all cannabis users in the studied countries,
which justify a focused look at these CO users with respect
to clinical features and problems associated with the drug
disorders. Separately, and with evidence from more coun-
tries, WMHS collaborators are following up this investiga-
tion with a look at all cannabis users, and are estimating the
influence of polydrug use on the occurrence of these clini-
cal features, but these analyses introduce a good bit of com-
plexity in the cross-national research context, as there is a
good deal of heterogeneity in the profile of internationally
regulated drugs used, plus large between-country variations
in the police responses to the different drug compounds.
Also, this study found that as a general rule the estimated
experience of CO users with respect to 'clinically signifi-
cant' cannabis problems did not vary appreciably across the
samples, even though there is a wide variation in the occur-
rence of cannabis use across these national boundaries
within the Americas. The exception to the rule was found in
the Colombia-USA contrast, with an excess occurrence of
cannabis-related legal and social problems in Colombia. We
speculate that the observed variation might be traced to dif-
ferences in the context in which cannabis is consumed in
each country, such as whether alcohol is being consumed
concurrently. Concurrent use of cannabis with alcohol has
been described in the epidemiological literature as the most
common pattern of polydrug use, and has been related to
excess occurrence of social and psychological conse-
quences [6,22], and also to behavioral patterns that might
promote adverse consequences, such as attending parties
more often [6,18]. Our use of AUD-matching and the exact
conditional logistic regression was motivated by an effort to
probe into this possibility, but AUD does not encompass the
concept of concurrent or simultaneous alcohol-cannabis
use, so this issue must be left for future investigations, with
deliberate assessment of concurrency and simultaneity of
alcohol and other drug use, as recommended elsewhere
[23].
When introducing our study in this paper's 'Background'
section, we also mentioned the possibility that the THC
content of smoked cannabis might vary considerably across
countries. We also mentioned other cross-country and
within-country variations in cannabis ingestion practices.
For example, our colleagues from western Europe, Turkey,
and Egypt were surprised to learn that in the Americas and
in New Zealand, the cannabis typically is smoked by itself,
and not in cannabis-tobacco formulations (with the excep-
tion of American 'blunts' - namely, hollowed out tobacco
cigars into which the cannabis is inserted and smoked). Our
colleagues from India were surprised at the narrow range of
cannabis preparations generally available in the Americas,
and brought to our attention many different teas, cakes, and
other formulations for cannabis in their country. The World
Mental Health Surveys were not focused specifically upon
cannabis, and gathered essentially no information about
these details of cannabis consumption. In future cross-
national research focused specifically upon cannabis con-
sumption, it may be possible to study cannabis-related
experiences with more careful probing into possibilities that
different cannabis experiences depend upon these cannabis
ingestion practices.
The evidence of this study also draws attention to some
unanswered questions about the experience of Latinos liv-
ing in the USA. In the WMH research, with similar survey
methods used for all places, it was found that 30% of US
Latinos had smoked cannabis (unpublished National Latino
and Asian American Study, NLAAS, estimate derived for
this study report), which is a value about halfway between
what was found for Colombia and Mexico (10-11% and 7-
8%, respectively) and the USA (42-43%) [14]; nonetheless,
there was no appreciable variation in the experience of clin-
ically significant cannabis problems in the USA general
population versus US Latino contrast. In future research
with larger sample sizes and a focus on these research
issues, it should be possible to examine these interesting
cannabis patterns in relation to (a) birth cohort variations,
(b) time elapsed since migration into the USA (including
the USA-born Latinos), other issues of acculturation,
assimilation, and adaptation, as has been done in relation toFiestas et al. BMC Public Health 2010, 10:152
http://www.biomedcentral.com/1471-2458/10/152
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the epidemiology of cardiovascular diseases [24,25] and
cancer [26,27]. Indeed, Borges and colleagues studied use
of alcohol and other psychoactive drugs among residents of
Mexico who had been in the USA at least once and then had
returned to Mexico, discovering that this subgroup had
greater drug involvement when compared to the subgroup
of Mexicans without USA experience stratified or holding
constant whether they had close family members who had
migrated to the USA [28].
Conclusion
Despite methodological limitations, this investigation has
shed new light on cross-national variation in the occurrence
of cannabis smoking and related problems among commu-
nity-dwelling adult residents of three countries of the
Americas and among Latino residents in the USA. In these
places, a majority of cannabis smoking adults had not
engaged in illegal use of cocaine, heroin or other drugs, and
among these 'cannabis only' users a very small minority
(<10%) had developed clinically significant clinical fea-
tures that we associate with cannabis use disorders as diag-
nosed by contemporary case definitions. As a general rule,
there was no appreciable cross-national variation in the
occurrence of these clinical features among 'cannabis only'
users, which suggests that the wide cross-national variabil-
ity of the cumulative incidence of cannabis use disorders
seen in different world reports may be due more to quantita-
tive differences in the number of people involved with this
drug across countries, rather than qualitative differences in
the experience of each of the cannabis problems under
study. Our finding that Colombia 'cannabis only' users had
more often experienced cannabis-associated social and
legal problems, as compared to 'cannabis only' users in the
USA general population deserves further investigation. Our
research group has offered speculations with respect to pos-
sible explanations for the observed Colombia-USA differ-
ence, but future studies will be required to confirm and to
produce more definitive evidence about the observed differ-
ence.
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